When is PathAI the better choice?

The deepest algorithm and regulatory pedigree: an A on AI centrality, more than 20 products, and AIM-MASH as the first pathology Drug Development Tool qualified by both the FDA and the EMA, a bar above device clearance. Model updates under a Predetermined Change Control Plan on the 2025 AISight Dx clearance, so changes follow a path agreed in advance rather than arriving silently. Depth across both clinical and biopharma settings, with a national reference laboratory having licensed the platform for its own pathology operations.

When is Proscia the better choice?

Independence, which is the differentiator here: no pending acquisition by a diagnostics manufacturer, so neutrality toward outside algorithms is not in question the way it is for a platform moving into Roche. The strongest published oversight posture: built around expert verification, with the company arguing the position publicly rather than only implementing it. The cleanest regulatory disclosure: FDA 510(k) and CE-IVDR for primary diagnosis, and a plain statement that its research edition is research use only and not for clinical diagnosis.

Head-to-Head

PathAI vs Proscia

Last VerifiedJuly 22, 2026

Verdict

Both are cleared platforms for primary diagnosis, so the real fork is pedigree versus independence. If your failure mode is standardizing on a platform that later gets absorbed by a diagnostics manufacturer which deprioritizes algorithms competing with its own assays, that risk is live for PathAI and not for Proscia. PathAI grades A on AI centrality and holds the deepest algorithm pedigree here, including AIM-MASH, the first pathology Drug Development Tool qualified by both the FDA and the EMA. But it is merging into Roche, which puts neutrality toward outside algorithms in question. Proscia stays independent, holds the strongest published oversight posture, and draws the cleared versus research use line more cleanly than almost anyone in the category.

Select PathAI if

The deepest algorithm and regulatory pedigree: an A on AI centrality, more than 20 products, and AIM-MASH as the first pathology Drug Development Tool qualified by both the FDA and the EMA, a bar above device clearance.
Model updates under a Predetermined Change Control Plan on the 2025 AISight Dx clearance, so changes follow a path agreed in advance rather than arriving silently.
Depth across both clinical and biopharma settings, with a national reference laboratory having licensed the platform for its own pathology operations.

Select Proscia if

Independence, which is the differentiator here: no pending acquisition by a diagnostics manufacturer, so neutrality toward outside algorithms is not in question the way it is for a platform moving into Roche.
The strongest published oversight posture: built around expert verification, with the company arguing the position publicly rather than only implementing it.
The cleanest regulatory disclosure: FDA 510(k) and CE-IVDR for primary diagnosis, and a plain statement that its research edition is research use only and not for clinical diagnosis.

Attribute Matrix

Side-by-Side

Axis	P PathAI	P Proscia
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Disclosure

Neither publishes pricing or a security attestation; SOC 2, HITRUST, and ISO 27001 are absent for both. The material fact on PathAI is its Roche merger, roughly 750 million dollars upfront plus up to 300 million in milestones, expected to close in the second half of 2026 and moving the company into Roche's Diagnostics division. External analysts have questioned whether an open algorithm platform stays neutral under a diagnostics owner with its own assay pipeline, and buyers should establish how existing licensing, including arrangements with reference laboratories, carries over. Proscia holds whole slide images and clinical metadata across both diagnostic and pharmaceutical research customers and publishes neither the boundary between those data environments nor its residency terms.